John A. Wagner

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

T. Rushmore, H. Greenberg, E. Carlini, 2009, Clinical pharmacology and therapeutics.

Effects of omeprazole on plasma levels of raltegravir.

H. Teppler, B. Nguyen, M. Iwamoto, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

L. V. Van Bortel, J. Wagner, K. Lasseter, 2013, British journal of clinical pharmacology.

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

J. Wagner, T. Marbury, K. Gottesdiener, 2008, Journal of clinical pharmacology.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

A. Tolcher, K. Papadopoulos, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.